In our previous T-ALL study9, we found that RNAi prodrugs targeting Plk1 could enter primary cells from T-ALL patients and induce knockdown of Plk1 mRNA followed by cell cycle arrest and apoptosis. This evidence concerns the gene PLK1 and acute lymphoblastic leukemia.